TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04855383
Drug: The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
Study: NCT03534648
Drug: PF-06865571 administered Day 7-14
Normalized name: Aminosyn-PF 7%
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-06865571 administered Q12hr on Days 7-14
Study: NCT03534648
Drug: PF-05221304 administered Day 7-14
Normalized name: Aminosyn-PF 7%
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-05221304 administered Q12hr Days 7-14
Study: NCT00193505
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193505
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193505
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193505
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04052737
Drug: Normal Saline along with standard treatment
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
Study: NCT00840463
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
Study: NCT00036790
Drug: motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03792009
Drug: 5% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT04083495
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
Study: NCT04083495
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
Study: NCT01857895
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
Study: NCT00165737
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03191786
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered via IV infusion once every three weeks (QW3).
Study: NCT03191786
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
Study: NCT03191786
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered per relevant local guidelines and SmPC management.
Study: NCT00295945
Drug: hydromorphone hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00295945
Drug: ropivacaine hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02569515
Drug: Epoetin Beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
Study: NCT00042809
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00042809
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01045447
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
Study: NCT01045447
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study: NCT01659918
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01659918
Drug: Singulair
Normalized name: Singulair
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02283814
Drug: Topamax
Normalized name: Topamax
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00826891
Drug: Cisplatin Combined With Topotecan
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2
Study: NCT02866682
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brand Drug for the duration of the study.
Study: NCT02866682
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic
Study: NCT00671281
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
Study: NCT03127449
Drug: Alflutinib
Normalized name: Alflutinib
DrugBank: Alflutinib (DB16087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients take Alflutinib orally once per day at different dose
Study: NCT00075881
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01149200
Drug: TC-6499
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg enteric-coated oral hard gelatin capsule, administered twice daily
Study: NCT00664170
Drug: ANX-514
Normalized name: hydroxyzine hydrochloride Oral Tablet [Anx]
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2
Study: NCT00664170
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2
Study: NCT00393562
Drug: modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00393562
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00520026
Drug: lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02224664
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses titrated up to 5mg QD
Study: NCT02224664
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses titrated up to 15 mg QD
Study: NCT02224664
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Study: NCT02224664
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses titrated up to 25 mg QD
Study: NCT01412879
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01412879
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01412879
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01412879
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02109029
Drug: Insulin Peglispro
Normalized name: Insulin peglispro
DrugBank: Insulin peglispro (DB11567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02109029
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03332069
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03184870
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03184870
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT03184870
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03184870
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03184870
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT00059657
Drug: Ecraprost in lipid emulsion
Normalized name: propofol lipid emulsion
DrugBank: Ecraprost (DB16148)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00476138
Drug: Epigallocatechin-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01538771
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
Study: NCT04101890
Drug: Diaper care with Theraworx
Normalized name: Vanicream Diaper Rash
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
Study: NCT03368859
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT03368859
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT03397186
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as standard of care
Study: NCT02354833
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00112476
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00112476
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00345605
Drug: Sodium Phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
Study: NCT03601897
Drug: Rebastinib
Normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03601897
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2
Study: NCT03518554
Drug: JAB-3068
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
Study: NCT02210780
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered via subcutaneous injection.
Study: NCT00003956
Drug: lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01689558
Drug: Recombine Endostatin
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
Study: NCT03542838
Drug: Resiniferatoxin
Normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiniferatoxin is a compound purified from natural sources.
Study: NCT03542838
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline is a normal physiological solution
Study: NCT00428168
Drug: Betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 24mg BID
Study: NCT00004255
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004255
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004255
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02966314
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
Study: NCT00054470
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03849729
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
Study: NCT01287754
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg daily orally
Study: NCT00928915
Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, repeated until INR ≤ 1.2
Study: NCT03754049
Drug: DSP
Normalized name: DSP107
DrugBank: DSP107 (DB17501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
Study: NCT04122196
Drug: Pregabalin 300mg
Normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
Study: NCT00492986
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Study: NCT01328379
Drug: Dalfampridine-ER 5mg
Normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, twice daily
Study: NCT01328379
Drug: Dalfampridine-ER 10mg
Normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, twice daily
Study: NCT00000378
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 week trial dose up to 200mgs
Study: NCT00000378
Drug: Nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 week trial dose adjusted to therapeutic level
Study: NCT00803556
Drug: Alvespimycin
Normalized name: Alvespimycin
DrugBank: Alvespimycin (DB12442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
Study: NCT00803556
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
Study: NCT00803556
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
Study: NCT01929083
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study: NCT01929083
Drug: Ibutilide
Normalized name: Ibutilide
DrugBank: Ibutilide (DB00308)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study: NCT00644592
Drug: Fenofibrate capsule daily for 4 weeks
Normalized name: Fenofibrate Capsules
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo capsule daily for 4 weeks
Study: NCT00644592
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg/day orally for 4 weeks
Study: NCT04390685
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
Study: NCT01075087
Drug: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Study: NCT00235521
Drug: aerosolized iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01049776
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
Study: NCT02113657
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg by vein once every 3 weeks for a total of 4 doses.
Study: NCT04328480
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.
Study: NCT01829048
Drug: PF-02545920
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
Study: NCT01829048
Drug: PF-02545920
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
Study: NCT01829048
Drug: PF-02545920
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
Study: NCT02561156
Drug: TAK-653 Placebo
Normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-653 placebo-matching tablets.
Study: NCT02561156
Drug: TAK-653
Normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-653 tablets.